FDA Approves Xyzal For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria

FDA Approves Xyzal For Use In Children Age Six Months And Older For
The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic
Urticaria
August 25, 2009
ATLANTA and BRIDGEWATER, N.J., Aug. 24 /PRNewswire/ -- UCB and
sanofi-aventis U.S. announced today that the U.S. Food and Drug
Administration (FDA) has approved Xyzal (levocetirizine
dihydrochloride) for children age six months and older for the relief
of symptoms of perennial allergic rhinitis (indoor allergies) and
chronic idiopathic urticaria (chronic hives) and for children age two
years and older for symptoms of seasonal allergic rhinitis (outdoor
allergies). Until now, Xyzal , a once-daily prescription...